Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical ...
Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years. He said years of R&D and $65 billion in acquisitions have ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
24/7 Wall St. on MSN
Eli Lilly vs. Merck: One is a no-brainer to hold through 2030
Quick ReadLilly's Q2 revenue surged 48% to $23 billion on Mounjaro and Zepbound strength; Merck grew just 5% as KEYTRUDA nears peak penetration.Lilly's raised FY2026 guidance of $85 to $87 billion and ...
Merck KGaA plans to appoint Constantin Beckmann as CEO effective May 1, 2026, following the annual general meeting. U.S. investors can access the stock via OTC Markets under MKGAF, gaining exposure to ...
27don MSN
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancer vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial ...
Technology is changing the way pharmaceutical companies discover and develop new drugs. For Matt Studney, who joined Merck as a chemical engineer, technology changed the course of his career. In 2017, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results